Molecular diagnostic company Asuragen Inc. has raised $7.5 million of a planned $15 million round of financing. The Austin-based company collected the capital from 15 investors, according to a Wednesday filing with the U.S. Securities and Exchange Commission. Asuragen, founded in 2006, is an offshoot of Ambion Inc., which launched in Austin in 1989. In 2005, Ambion founder and CEO Matt Winkler sold Ambion’s research re-agent business to focus on Asuragen’s miRNA-based therapeutic and diagnostic products. It employs 124 workers in Austin.
